Sam Wilson

Dr. Sam Wilson


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2011 in Nature
Verified
Journal Article
Open access
PDF file
JSJohn W. Schoggins
John W. Schoggins
SWSam Wilson
Sam Wilson
MPMaryline Panis
Maryline Panis
MMMary Y. Murphy
Mary Y. Murphy
CJChristopher T. Jones
Christopher T. Jones
CRCharles Rice
Charles Rice
There is growing interest in antiviral interferon-stimulated genes (ISGs), such as IFITM3 and BST2 (also known as tetherin), because of their potential as drug targets. An overexpression screen has been used to assess the impact of several hundred ISGs on the replication of a number of viruses, including HIV-1 and hepatitis C virus. Combinations of validated antiviral ISGs were found to have additive effects and to converge on translational inhibition. Surprisingly, some ISGs actually enhance the replication of certain viruses, underlining the complexity of the response to interferon. The type I interferon response protects cells against invading viral pathogens. The cellular factors that mediate this defence are the products of interferon-stimulated genes (ISGs). Although hundreds of ISGs have been identified since their discovery more than 25 years ago1,2,3, only a few have been characterized with respect to antiviral activity. For most ISG products, little is known about their antiviral potential, their target specificity and their mechanisms of action. Using an overexpression screening approach, here we show that different viruses are targeted by unique sets of ISGs. We find that each viral species is susceptible to multiple antiviral genes, which together encompass a range of inhibitory activities. To conduct the screen, more than 380 human ISGs were tested for their ability to inhibit the replication of several important human and animal viruses, including hepatitis C virus, yellow fever virus, West Nile virus, chikungunya virus, Venezuelan equine encephalitis virus and human immunodeficiency virus type-1. Broadly acting effectors included IRF1, C6orf150 (also known as MB21D1), HPSE, RIG-I (also known as DDX58), MDA5 (also known as IFIH1) and IFITM3, whereas more targeted antiviral specificity was observed with DDX60, IFI44L, IFI6, IFITM2, MAP3K14, MOV10, NAMPT (also known as PBEF1), OASL, RTP4, TREX1 and UNC84B (also known as SUN2). Combined expression of pairs of ISGs showed additive antiviral effects similar to those of moderate type I interferon doses. Mechanistic studies uncovered a common theme of translational inhibition for numerous effectors. Several ISGs, including ADAR, FAM46C, LY6E and MCOLN2, enhanced the replication of certain viruses, highlighting another layer of complexity in the highly pleiotropic type I interferon system.

13 October 2013 in Nature
Verified
Journal Article
Closed access
PDF file
MKMelissa Kane
Melissa Kane
SYShalini S. Yadav
Shalini S. Yadav
JBJulia Bitzegeio
Julia Bitzegeio
SKSebla B. Kutluay
Sebla B. Kutluay
TZTrinity Zang
Trinity Zang
PBPaul D. Bieniasz
Paul D. Bieniasz

18 December 2017 in PLOS Biology
Verified
Journal Article
Open access
PDF file
ASAndrew E Shaw
Andrew E Shaw
JHJoseph Hughes
Joseph Hughes
QGQuan Gu
Quan Gu
ABAbdelkader Behdenna
Abdelkader Behdenna
JSJoshua Singer
Joshua Singer
MPMassimo Palmarini
Massimo Palmarini
The host innate immune response mediated by type I interferon (IFN) and the resulting up-regulation of hundreds of interferon-stimulated genes (ISGs) provide an immediate barrier to virus infection. Studies of the type I ‘interferome’ have mainly been carried out at a single species level, often lacking the power necessary to understand key evolutionary features of this pathway. Here, using a single experimental platform, we determined the properties of the interferomes of multiple vertebrate species and developed a webserver to mine the dataset. This approach revealed a conserved ‘core’ of 62 ISGs, including genes not previously associated with IFN, underscoring the ancestral functions associated with this antiviral host response. We show that gene expansion contributes to the evolution of the IFN system and that interferomes are shaped by lineage-specific pressures. Consequently, each mammal possesses a unique repertoire of ISGs, including genes common to all mammals and others unique to their specific species or phylogenetic lineages. An analysis of genes commonly down-regulated by IFN suggests that epigenetic regulation of transcription is a fundamental aspect of the IFN response. Our study provides a resource for the scientific community highlighting key paradigms of the type I IFN response. The type I interferon (IFN) response is triggered upon sensing of an incoming pathogen in an infected cell and results in the expression of hundreds of IFN-stimulated genes (ISGs, collectively referred to as ‘the interferome’). Studies on the interferome have been carried out mainly in human cells and therefore often lack the power to understand comparative evolutionary aspects of this critical pathway. In this study, we characterized the interferome in several animal species (including humans) using a single experimental framework. This approach allowed us to identify fundamental properties of the innate immune system. In particular, we revealed 62 ‘core’ ISGs, up-regulated in response to IFN in all vertebrates, highlighting the ancestral functions of the IFN system. In addition, we show that many genes repressed by the IFN response normally function as regulators of cell transcription. ISGs shared by multiple species have a higher propensity than other genes to exist as multiple copies in the genome. Importantly, we observed that genes have arisen as ISGs throughout evolution. Hence, every animal species possesses a unique repertoire of ISGs that includes core and lineage-specific genes. Collectively, our data provide a framework on which it will be possible to test the role of the IFN response in pathogen emergence and cross-species transmission.

4 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JTJohn R Tyson
John R Tyson
PJPhillip James
Phillip James
DSDavid Stoddart
David Stoddart
NSNatalie Sparks
Natalie Sparks
AWArthur Wickenhagen
Arthur Wickenhagen
JQJoshua Quick
Joshua Quick
Genome sequencing has been widely deployed to study the evolution of SARS-CoV-2 with more than 90,000 genome sequences uploaded to the GISAID database. We published a method for SARS-CoV-2 genome sequencing ( https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w ) online on January 22, 2020. This approach has rapidly become the most popular method for sequencing SARS-CoV-2 due to its simplicity and cost-effectiveness. Here we present improvements to the original protocol: i) an updated primer scheme with 22 additional primers to improve genome coverage, ii) a streamlined library preparation workflow which improves demultiplexing rate for up to 96 samples and reduces hands-on time by several hours and iii) cost savings which bring the reagent cost down to £10 per sample making it practical for individual labs to sequence thousands of SARS-CoV-2 genomes to support national and international genomic epidemiology efforts.

1 July 2009 in Cell Host & Microbe
Verified
Journal Article
Closed access
FZFengwen Zhang
Fengwen Zhang
SWSam Wilson
Sam Wilson
WLWilmina C. Landford
Wilmina C. Landford
BVBeatriz Virgen
Beatriz Virgen
DGDevon Gregory
Devon Gregory
THTheodora Hatziioannou
Theodora Hatziioannou

1 September 2016 in Cell Host & Microbe
Verified
Journal Article
Open access
MKMelissa Kane
Melissa Kane
TZTrinity M. Zang
Trinity M. Zang
SRSuzannah J. Rihn
Suzannah J. Rihn
FZFengwen Zhang
Fengwen Zhang
TKTonya Kueck
Tonya Kueck
PBPaul D. Bieniasz
Paul D. Bieniasz
Interferons (IFNs) exert their anti-viral effects by inducing the expression of hundreds of IFN-stimulated genes (ISGs). The activity of known ISGs is insufficient to account for the antiretroviral effects of IFN, suggesting that ISGs with antiretroviral activity are yet to be described. We constructed an arrayed library of ISGs from rhesus macaques and tested the ability of hundreds of individual macaque and human ISGs to inhibit early and late replication steps for 11 members of the retroviridae from various host species. These screens uncovered numerous ISGs with antiretroviral activity at both the early and late stages of virus replication. Detailed analyses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retroviral replication by metabolite depletion while tripartite motif-56 (TRIM56) accentuates ISG induction by IFNα and inhibits the expression of late HIV-1 genes. Overall, these studies reveal numerous host proteins that mediate the antiretroviral activity of IFNs.